Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Status:
Suspended
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to
an earlier detection of the primary tumour and a better prognosis, but melanoma remains an
aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies
compared groups of patients diagnosed with primary melanoma and treated with betablockers for
another indication to patients who never received betablockers. In these three studies, the
outcome of the disease is significantly better for people under betablocker treatment with a
decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate
the efficacy and the tolerability of an adjuvant treatment with propranolol for patients
suffering from a primary melanoma with a high risk of recurrence.